Evaluating The Performance Of CellGenix® GMP TCM And CellGenix® Cytokines In CAR-T Processes

By Benedikt Steinle, Evelien Nijssen, Sarah Carqueville, Ursula Schultz, Charlotte Tardivet

Cell and gene therapies like chimeric antigen receptor (CAR) T cell therapy hold significant promise in the treatment of various diseases. However, the successful production of these therapies requires manufacturers to address operational hurdles associated with novel and emerging modalities.

This study examines the utilization of CellGenix® GMP T cell culture medium (TCM) and cytokines to produce functional CAR-T cells exhibiting an early differentiated memory T cell phenotype. The expansion, functionality, and phenotype of CAR-T cells cultured in CellGenix® GMP TCM are evaluated compared to other commercially available T cell media. These findings provide insights into the potential of CellGenix® GMP TCM to enhance the CAR-T cell manufacturing process.